Search clinical trials for: myRisk genetic testing

Total 23485 results

University Hospital, Brest

Recruiting

Metabolic Exercise Testing (RANNOU)

Myalgia | Exercise Test | Metabolic Myopathies

France
National Institute on Aging (NIA)

Recruiting

Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT)

Healthy Volunteers | Non-Healthy/Non-Frail | Frail

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Novel Genetic Disorders of the Immune System

CTLA4 | PI3KCD | STAT3GOF | MAGT1

United States
MiraKind

Recruiting

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

Cancer

United States
National Cancer Institute (NCI)

Recruiting

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7

United States, Guam, Puerto Rico
University of Florida

Recruiting

Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

Alpha-1 Antitrypsin Deficiency | Cystic Fibrosis (CF) | AATD | AAT Deficiency

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Melanoma | Sarcoma

United States
National Cancer Institute (NCI)

Recruiting

Clinical and Genetic Studies of Li-Fraumeni Syndrome

Neoplasms | Li-Fraumeni Syndrome | Tp53 Mutations

United States
University of Florida
University of California, Los Angeles; National Ataxia Foundation

Recruiting

Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

Spinocerebellar Ataxia Type 3 | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6

United States
Columbia University
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science (DHREAMS)

Congenital Diaphragmatic Hernia

United States, Egypt
University of Florida

Recruiting

The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study (ACT)

Alpha-1 Antitrypsin Deficiency

United States
University of Miami
ALS Association

Recruiting

The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study (Pre-fALS)

Amyotrophic Lateral Sclerosis

United States
Connecticut Children's Medical Center
Johns Hopkins University; Eunice Kennedy Shriver National Institute of Child... and other collaborators

Recruiting

Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

Albright Hereditary Osteodystrophy | Pseudopseudohypoparathyroidism | Pseudohypoparathyroidism Type 1A

United States
University of Chicago

Recruiting

Genetics of Cardiovascular and Neuromuscular Disease

Muscular Dystrophy | Arrhythmia | Cardiomyopathy

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Consent for Use of Stored Patient Specimens for Future Testing

HIV Infections

United States, Puerto Rico
Abramson Cancer Center at Penn Medicine

Enrolling by invitation

Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition

Ovarian Cancer | Genetic Predisposition to Disease | Breast Cancer Female | Hereditary Diseases | Gene Mutation-Related Cancer | Hereditary Breast and Ovarian Cancer | Hereditary Cancer Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Pfizer

Active, not recruiting

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

Dermatitis, Atopic

China, United States, Spain, Taiwan, Germany, Australia, Canada, Hungary, Korea, Republic of, Poland, Serbia, Bulgaria, Czechia, Japan, Latvia, United Kingdom, Belgium, Israel, Italy, Finland, Mexico, Romania, Slovakia, Argentina, Brazil, Chil... and more
National Institute on Deafness and Other Communication...

Completed

Genetic Linkage Studies of Stuttering

Stuttering

United States, Japan, Pakistan
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
Abramson Cancer Center at Penn Medicine

Active, not recruiting

Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model

Genetic Predisposition to Disease | Prostate Cancer | Pancreas Cancer | Hereditary Cancer

United States
Children's Hospital of Philadelphia

Completed

Neurocognitive Outcomes and Quality of Life in Adults With Maple Syrup Urine Disease (MSUD)

Maple Syrup Urine Disease

United States
Merck Sharp & Dohme LLC

Completed

Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)

Dermatitis, Atopic

United States, Belgium, Bulgaria, Canada, Romania, Spain
Universiteit Antwerpen
University Hospital, Antwerp; Cliniques universitaires Saint-Luc- Université...

Completed

Gaining Insight Into the Complexity of Pain in Patients With Haemophilia

Hemophilia A | Hemophilia B

Belgium
Virginia Commonwealth University

Completed

Feasibility Study: Educational Genetic Test Video

Prostate Cancer | Education

United States
Eli Lilly and Company
Dermira, Inc.

Active, not recruiting

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) (ADjoin)

Atopic Dermatitis

United States, Spain, Canada, France, Korea, Republic of, Taiwan, Australia, Germany, Bulgaria, Estonia, Latvia, Lithuania, Mexico, Poland, Singapore, Ukraine
Paul S. Bernstein

Active, not recruiting

The Moran AMD Genetic Testing Assessment Study (MAGENTA)

Age-Related Macular Degeneration | Genetic Testing | Nutritional Biomarkers

United States
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

Improving Uptake of Genetic Cancer Risk Assessment in African American Women- Video

Breast Cancer

United States
Pfizer

Terminated

A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

Eczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, Unspecified

United States, Canada, Czechia, Poland
Inmagene LLC

Terminated

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)

Atopic Dermatitis | Moderate-to-severe Atopic Dermatitis | AD

Canada, United States
University of Washington
National Cancer Institute (NCI)

Active, not recruiting

Genetic Testing for Men With Metastatic Prostate Cancer (GENTleMEN)

Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8

United States
Case Comprehensive Cancer Center

Active, not recruiting

Effectiveness of AI Genetic Counseling Program vs In-person Genetic Counseling in Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Duke University

Active, not recruiting

Genetic Testing to Understand and Address Renal Disease Disparities Across the United States (GUARDD-US)

Hypertension | Renal Disease

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States

Search clinical trials for: myRisk genetic testing

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations